Project Grant R37CA304011
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $389K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $2.433959 million on August 13, 2026, under the Cancer Centers Support Grants program (CFDA 93.397), with performance concluding July 31, 2031, at the recipient's Boston, Massachusetts location. The award funds a Specialized Program of Research Excellence (SPORE) in Leukemia designed to improve understanding of the genetic and molecular basis of myeloid leukemia and acquired resistance to treatment, and to develop novel...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $233,478 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize and target acquired resistance to menin-KMT2A inhibitors in acute myeloid leukemia. The award funds research profiling patient samples and patient-derived xenograft models to identify gain-of-function mutations in an oncogenic chromatin complex composed of menin, KMT2A, and PSIP1 proteins that confer resistance to menin...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $1.547 million in project grant R37CA295653 on September 17, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Dana-Farber will develop and deploy ACTIVATE, an open-source AI-driven tool to improve cancer clinical trial feasibility assessment and patient-trial matching. The tool extends Dana-Farber's existing MatchMiner platform to extract clinical variables—including cancer type, stage,...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $432,050 on August 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop peptide-MHC pseudotyped retroviral vectors for in vivo gene delivery to antigen-specific T cells as a novel cancer immunotherapy approach. The work addresses a gap in current cancer immunotherapies by combining attributes of CAR-T cell therapies with tumor-infiltrating lymphocyte and immune checkpoint blockade...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $409,463 on June 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate eukaryotic translation initiation factor 4A (EIF4A) inhibition as a therapeutic approach for acute myeloid leukemia. The research validates zotatifin, a clinical-grade EIF4A inhibitor, as a small molecule to target AML cells. The central hypothesis is that zotatifin selectively targets AML cells over healthy cells and...
- The National Cancer Institute awarded Emory University $639,859 under the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, to support research targeting non-genetic and genetic mechanisms of drug resistance in acute myeloid leukemia. The research addresses how most AML patients develop resistance to chemotherapy or targeted therapy, leading to relapse and death. The project applies dynamic BH3 profiling and patient-derived xenograft models to understand how resistance emerges,...